The effect on serum prolactin, LH and FSH levels of 25 \g=m\gethinyl-oestradiol administered daily per os during 27 consecutive days was investigated in 5 post-menopausal women aged 52-78. Blood samples were collected before, during and after treatment. The hormones were assayed in serum by radioimmunological methods. Both LH and FSH decreased progressively and significantly from 120 and 115 mIU/ml before treatment to 52 and 51 mIU/ml, respectively after three weeks of oestrogen administration. Two weeks after interruption of treatment, LH (90 mIU/ml) and FSH (112 mIU/ml) were significantly higher than during the last week of treatment.
In women with regular menstrual cycles prolactin secretion is stimulated by exogenous oestrogens but at relatively high doses: 200 fig of ethinyloestadiol or more (Robyn et al. 1975) .
The purpose of the present study was (Sinha et al. 1973; Badawi et al. 1974) , LH (Robyn et al. 1971) and FSH (Odell Se Hescox 1972 
RESULTS
As shown in Fig. 1 both mean serum LH and FSH levels decreased pro¬ gressively and significantly (P <C 0.001) from 120 and 115 mIU/ml before treatment to 52 and 51 mIU/ml, respectively, after 21 days of daily adminis¬ tration of 25 fig ethinyloestradiol. Two weeks after termination of treatment, LH (90 mIU/ml) and FSH (112 mIU/ml) were significantly higher (P < 0.001) than during the last week of treatment (52 and 51 mIU/ml, respectively).
As shown in Fig. 2 (Robyn 8c Vekemans, in press) and this fall is parallel to that reported for circulating oestrogens (Longcope 1971) and for urinary oestrogens (Pincus el al. 1954; Furuhjelm 1966) . Thus oestrogens can be regarded as an important physiological factor in the control of prolactin secretion both in animals and men.
It has also been found that in hypogonadal women a daily dose of 1 fig/kg body weight of ethinyloestradiol induces a significant rise in serum prolactin (Yen et al. 1974 (Meites 1972 (Meites , 1973 . It has been reported that women treated for prolonged periods of time with drugs known to release prolactin such as reserpine show an increased incidence of breast cancer (Eltigi et al. 1973; Armstrong et al. 1974; Heinonen et al. 1974 ). Therefore, it should be considered that elevated prolactin levels resulting from chronic treatment with oestrogens might increase the risk of breast cancer in post¬ menopausal women.
